This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue

You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.


Go back


Single Inhaler Triple Therapy in COPD; Evidence to Action


Our experts Professor Dave Singh and Dr Sanjeev Rana will present and discuss the evidence base for TrelegyEllipta (fluticasone furoate, umeclidinium, vilanterol) and Single Inhaler Triple Therapies in COPD, sharing how this can be applied in clinical practice.

Throughout the webinar, the expert speakers will focus on:
- The role of Single Inhaler Triple Therapy in the treatment of symptomatic COPD patients at risk of an exacerbation.
- The evidence base for TrelegyEllipta (fluticasone furoate, umeclidinium, vilanterol) and other relevant data for triple therapies; both single and multiple inhaler.
- Practical considerations for HCPs that are optimising inhaler use for COPD patients, including environmental impact and device choice.

The expert panel has a wide range of expertise covering both primary and secondary care.

You can expect practical and informative advice on the treatment options for symptomatic COPD patients at risk of an exacerbation.

Webinar Date | 26th May 2021 | at 12:30 and 19:30



Professor Dave Singh

Professor of Clinical Pharmacology and Respiratory Medicine at the University of Manchester.

Professor Dave Singh graduated in medicine from Cambridge University and then specialised in clinical pharmacology and respiratory medicine. His research interest is the development of new drugs for asthma and COPD. He is the medical director of the Medicines Evaluation Unit, where he has acted as principal investigator in over 300 clinical trials. He is a member of the GOLD Science Committee. Currently, he is the chair of the European Respiratory Society airway pharmacology group, and an editor of the European Respiratory Journal and European Respiratory Review. He is a fellow of the European Respiratory Society and of the British Pharmacology Society. He has over 350 publications.


Dr Sanjeev Rana

General Practitioner, Respiratory GPwER, Medical Director, Clinical Commissioner and a Member of the Service Development Committee for the PCRS-UK

Dr Sanjeev Rana graduated from the Imperial School of Medicine and Technology in 1995 and he has a keen interest in population-based healthcare, applying international healthcare models to optimise healthcare utilisation, developing the NHS workforce and understanding what value means to the NHS

Adverse events should be reported. Reporting forms and information can be found at or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on +44 (0)800 221 441